Reading List - Emory Vaccine Center Immunology Core Laboratory - January 2006
A periodically updated list of papers of interest to members fo the EVC ICL
Breathnach, C.C., Clark, H. J., Clark, R. C., Olsen, C. W., Townsend, H. G., Lunn, D. P..
Vaccine, (2005).
"Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge."
Koopman, G., Mortier, D., Niphuis, H., Farese, A. M., Kahn, L. E., Mann, D., Wagner, R., MacVittie, T. J., Woulfe, S. L., Heeney, J. L..
Vaccine, 23(33), 4195-202. (2005).
"Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy."
Prlic, M., Gibbs, J., Jameson, S. C..
J Immunol, 175(4), 2152-7. (2005).
"Characteristics of NK cell migration early after vaccinia infection."
Price, D.A., Brenchley, J. M., Ruff, L. E., Betts, M. R., Hill, B. J., Roederer, M., Koup, R. A., Migueles, S. A., Gostick, E., Wooldridge, L., Sewell, A. K., Connors, M., Douek, D. C..
J Exp Med, (2005).
"Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses."
Guerra, S., López-Fernández, L. A., Pascual-Montano, A., Nájera, J. L., Zaballos, A., Esteban, M..
J Virol, 80(2), 985-98. (2006).
"Host Response to the Attenuated Poxvirus Vector NYVAC: Upregulation of Apoptotic Genes and NF-{kappa}B-Responsive Genes in Infected HeLa Cells."
Cicala, C., Arthos, J., Censoplano, N., Cruz, C., Chung, E., Martinelli, E., Lempicki, R. A., Natarajan, V., Vanryk, D., Daucher, M., Fauci, A. S..
Virology, (2005).
"HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells."
Ami, Y., Izumi, Y., Matsuo, K., Someya, K., Kanekiyo, M., Horibata, S., Yoshino, N., Sakai, K., Shinohara, K., Matsumoto, S., Yamada, T., Yamazaki, S., Yamamoto, N., Honda, M..
J Virol, 79(20), 12871-9. (2005).
"Priming-Boosting Vaccination with Recombinant Mycobacterium bovis Bacillus Calmette-Guerin and a Nonreplicating Vaccinia Virus Recombinant Leads to Long-Lasting and Effective Immunity."
Barba-Spaeth, G., Longman, R. S., Albert, M. L., Rice, C. M..
J Exp Med, 202(9), 1179-84. (2005).
"Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes."
de Bree, G.J., van Leeuwen, E. M., Out, T. A., Jansen, H. M., Jonkers, R. E., van Lier, R. A..
J Exp Med, 202(10), 1433-42. (2005).
"Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung."
Larke, N., Murphy, A., Wirblich, C., Teoh, D., Estcourt, M. J., McMichael, A. J., Roy, P., Hanke, T..
J Virol, 79(23), 14822-33. (2005).
"Induction of Human Immunodeficiency Virus Type 1-Specific T Cells by a Bluetongue Virus Tubule-Vectored Vaccine Prime-Recombinant Modified Virus Ankara Boost Regimen."
Kirwan, S., Merriam, D., Barsby, N., McKinnon, A., Burshtyn, D. N..
Virology, (2005).
"Vaccinia virus modulation of natural killer cell function by direct infection."
Vollmar, J., Arndtz, N., Eckl, K. M., Thomsen, T., Petzold, B., Mateo, L., Schlereth, B., Handley, A., King, L., Hülsemann, V., Tzatzaris, M., Merkl, K., Wulff, N., Chaplin, P..
Vaccine, (2005).
"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine."
Koff, W.C., Johnson, P. R., Watkins, D. I., Burton, D. R., Lifson, J. D., Hasenkrug, K. J., McDermott, A. B., Schultz, A., Zamb, T. J., Boyle, R., Desrosiers, R. C..
Nat Immunol, 7(1), 19-23. (2006).
"HIV vaccine design: insights from live attenuated SIV vaccines."
Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E., Darwin, S. C., Fast, P. E., Conlon, C., Rowland-Jones, S., McMichael, A. J., Hanke, T..
Vaccine, (2005).
"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers."
Slyker, J.A., Lohman, B. L., Mbori-Ngacha, D. A., Reilly, M., Wee, E. G., Dong, T., McMichael, A. J., Rowland-Jones, S. L., Hanke, T., John-Stewart, G..
Vaccine, 23(38), 4711-9. (2005).
"Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants."
Okeke, M.I., Nilssen, O., Traavik, T..
J Gen Virol, 87(Pt 1), 21-7. (2006).
"Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines."
Clark, R.H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C., Smith, G. L..
J Gen Virol, 87(Pt 1), 29-38. (2006).
"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy."
Kloosterboer, N., Groeneveld, P. H., Jansen, C. A., van der Vorst, T. J., Koning, F., Winkel, C. N., Duits, A. J., Miedema, F., van Baarle, D., van Rij, R. P., Brinkman, K., Schuitemaker, H..
Virology, 339(1), 70-80. (2005).
"Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus."
Johnston, J.B., Barrett, J. W., Nazarian, S. H., Goodwin, M., Ricuttio, D., Wang, G., McFadden, G..
Immunity, 23(6), 587-98. (2005).
"A Poxvirus-Encoded Pyrin Domain Protein Interacts with ASC-1 to Inhibit Host Inflammatory and Apoptotic Responses to Infection."
Zhan, X., Martin, L. N., Slobod, K. S., Coleclough, C., Lockey, T. D., Brown, S. A., Stambas, J., Bonsignori, M., Sealy, R. E., Blanchard, J. L., Hurwitz, J. L..
Vaccine, 23(46-47), 5306-20. (2005).
"Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV."
Hanke, T., McMichael, A. J., Dennis, M. J., Sharpe, S. A., Powell, L. A., McLoughlin, L., Crome, S. J..
Vaccine, 23(12), 1507-14. (2005).
"Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice."